Tempus Fugit, Investors Regret? Short Seller Targets AI Darling, Warns CEO Is 'Cash Out King'Benzinga • 05/28/25
A Decade of Discovery: Tempus Supported Almost 1,500 Research Projects in 10 YearsBusiness Wire • 05/28/25
Tempus AI vs. Butterfly: Which AI Health Tech Stock is the Better Buy?Zacks Investment Research • 05/26/25
These Investors Search for ‘Extreme Winners.' Why Aurora, BYD, Tempus AI Make the Cut.Barrons • 05/23/25
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination TreatmentBusiness Wire • 05/20/25
After 92% YTD Surge, Is Tempus AI a Buy on Trump's Executive Order?Zacks Investment Research • 05/15/25
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer PipelineBusiness Wire • 05/14/25
Artificial Intelligence (AI) in Clinical Trials Market Insights, Competitive Landscape, and Forecasts Report 2025-2032 Featuring Key Players Such as TEMPUS, NetraMark, ConcertAI, AiCure, and OracleGlobeNewsWire • 05/14/25
Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma DealsBenzinga • 05/07/25
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time.The Motley Fool • 05/02/25
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and EnrollmentBusiness Wire • 05/01/25